紫杉醇、紫杉醇脂质体和白蛋白结合型紫杉醇在头颈肿瘤中的疗效比较

郑璐; 胡静; 许权; 叶栋; 童晶涛; 王晶晶

引用本文:	郑璐,胡静,许权,叶栋,童晶涛,王晶晶.紫杉醇、紫杉醇脂质体和白蛋白结合型紫杉醇在头颈肿瘤中的疗效比较[J].中国现代应用药学,2019,36(11):1391-1394.
	ZHENG Lu,HU Jing,XU Quan,YE Dong,TONG Jingtao,WANG Jingjing.Comparison of the Efficacy of Paclitaxel, Paclitaxel Liposome and Albumin Bound Paclitaxel in Head and Neck Tumors[J].Chin J Mod Appl Pharm(中国现代应用药学),2019,36(11):1391-1394.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 3761次下载 1471次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
紫杉醇、紫杉醇脂质体和白蛋白结合型紫杉醇在头颈肿瘤中的疗效比较
郑璐, 胡静, 许权, 叶栋, 童晶涛, 王晶晶
宁波市医疗中心李惠利医院放疗科, 浙江宁波 315040

摘要:

目的探讨紫杉醇（paclitaxel，PTX）、PTX脂质体（paclitaxel liposome，L-PTX）和白蛋白结合型PTX（albumin bound paclitaxel，nab-PTX）在头颈肿瘤中的疗效。方法采用回顾性研究，收集整理2017年1月-2018年6月69例宁波市医疗中心李惠利医院头颈恶性肿瘤患者的临床资料，其中31例PTX联合卡铂治疗为PTX组，26例L-PTX联合卡铂治疗为L-PTX组，12例nab-PTX联合卡铂治疗为nab-PTX组。比较3组患者近期临床疗效以及不良反应情况。结果 Nab-PTX组患者的近期疗效优于PTX组（66.67%vs 32.26%，χ²=4.209，P=0.040）。L-PTX组患者中性粒细胞减少发生率高于PTX组（χ²=4.079，P=0.043），白细胞减少发生率高于PTX组（χ²=4.422，P=0.035）和nab-PTX组（χ²=5.640，P=0.018）；nab-PTX组患者脱发、恶心呕吐、腹泻等不良反应发生率低于PTX组（χ²=5.530，P=0.019；χ²=6.423，P=0.011；χ²=4.438，P=0.035）和L-PTX组（χ²=5.025，P=0.025；χ²=5.025，P=0.025；χ²=5.088，P=0.024），周围神经炎发生率低于PTX组（χ²=4.711，P=0.030）。结论 Nab-PTX联合卡铂治疗头颈肿瘤的近期疗效显著，患者不良反应明显减少。

关键词: 紫杉醇紫杉醇脂质体白蛋白结合型紫杉醇头颈肿瘤

DOI：10.13748/j.cnki.issn1007-7693.2019.11.016

分类号:R969.4

基金项目:宁波市自然科学基金项目（2018A610361）；宁波市领军和拔尖人才培养工程择优资助科研项目（NBLJ201801032）；浙江省医药卫生平台计划（骨干人才B类）（2015RCB025）

Comparison of the Efficacy of Paclitaxel, Paclitaxel Liposome and Albumin Bound Paclitaxel in Head and Neck Tumors

ZHENG Lu, HU Jing, XU Quan, YE Dong, TONG Jingtao, WANG Jingjing

Department of Radiotherapy, Ningbo Medical Center Lihuili Hospital, Ningbo 315040, China

Abstract:

OBJECTIVE To investigate the efficacy of paclitaxel(PTX), PTX liposome(L-PTX) and albumin bound paclitaxel(nab-PTX) in head and neck tumors. METHODS A total of 69 patients with head and neck cancer who were admitted to our hospital from January 2017 to June 2018 were enrolled. Among them, 31 patients received PTX plus carboplatin as PTX group, 26 patients received L-PTX plus carboplatin as L-PTX group, 12 patients received nab-PTX combined with carboplatin as nab-PTX group. The short-term clinical efficacy and adverse reactions of the 3 groups were compared. RESULTS The response rate of the nab-PTX group was higher than that of the PTX group(66.67% vs 32.26%, χ²=4.209, P=0.040); the incidence of neutropenia in the L-PTX group was higher than in the PTX group(χ²=4.079, P=0.043), and the incidence of leukopenia was higher than in the PTX group(χ²=4.422, P=0.035) and the nab-PTX group(χ²=5.640, P=0.018); the incidence of adverse reactions such as alopecia, nausea and vomiting, diarrhea in the nab-PTX group was lower than that in the PTX group(χ²=5.530, P=0.019; χ²=6.423, P=0.011; χ²=4.438, P=0.035) and L-PTX group(χ²=5.025, P=0.025; χ²=5.025, P=0.025; χ²=5.088, P=0.024), the incidence of peripheral neuritis was lower than that of PTX group(χ²=4.711, P=0.030). CONCLUSION Nab-PTX combined with carboplatin is effective in the treatment of head and neck tumors, and the adverse reactions are milder.

Key words: paclitaxel(PTX) paclitaxel liposome(L-PTX) albumin bound paclitaxel(nab-PTX) head and neck tumors